Stock-research Ratings: Ampio Pharmaceuticals, Inc. (AMPE), InspireMD, Inc. (NSPR)

Ampio Pharmaceuticals, Inc. (NYSE:AMPE) tinted loss of -0.98% (-0.01 points) to US$0.59. The volume of 0.64 Million shares climbed down over an trading activity of 1.12 Million shares. EPS ratio determined by looking at last 12 month figures is -0.23. Over the same time span, the stock marked US$3.89 as its best level and the lowest price reached was US$0.35. The corporation has a market cap of US$60.27 Million.

Ampio Pharmaceuticals, Inc. (NYSE:AMPE)’s earnings per share has been growing at a -18.4 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -489.2 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 23.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

InspireMD, Inc. (NYSE:NSPR) is worth US$7.29 Million and has recently risen 0.63% to US$0.18. The latest exchange of 0.92 Million shares is below its average trading activity of 1.24 Million shares. The day began at US$0.17 but the price moved to US$0.17 at one point during the trading and finally capitulating to a session high of US$0.17. The stock tapped a 52-week high of US$7.8 while the mean 12-month price target for the shares is US$3.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.65, and a price to sales ratio of 2.02. For the past 5 years, the company’s revenue has grown -10.7%, while the company’s earnings per share has grown 0%. With an institutional ownership near 10%, it carries an earnings per share ratio of -57.85.